|  |
| --- |
| **Testing for B-Type Natriuretic Peptide in the Diagnosis and Assessment of Heart Failure:What are the Nuances?** |

|  |
| --- |
|  |
| **Roundtable Panelists** **James B. Young, MD***Roundtable Moderator and Supplement Editor*Chairman, Division of MedicineHead, Section of Heart Failure, Department of Cardiovascular MedicineCleveland Clinic FoundationCleveland, Ohio**Natalie G. Correia, DO**Associate Director, Internal Medicine ResidencyStaff, Department of General Internal Medicine Cleveland Clinic FoundationCleveland, Ohio**Gary S. Francis, MD**Professor of Medicine, Cleveland Clinic Lerner College of MedicineStaff, Department of Cardiovascular MedicineCleveland Clinic FoundationCleveland, Ohio**Alan Maisel, MD**Professor of Medicine, University of California, San Diego, School of MedicineDirector, Coronary Care Unit, La Jolla VA Medical CenterSan Diego, Calif.**Franklin Michota, MD**Head, Section of Hospital MedicineDepartment of General Internal MedicineCleveland Clinic FoundationCleveland, Ohio**Panelist Disclosures**The following panelists reported that they have a relationship that, in the context of this supplement, could be perceived as a potential conflict of interest: • *James B. Young, MD*, reported that he has received grant/research support from Biosite Inc.• *Gary S. Francis, MD*, reported that he serves on an advisory board to Biosite Inc.• *Alan Maisel, MD*, reported that he has received grant/research support from, serves as a consultant to, and is on the speakers’ bureau of Biosite Inc. He also reported that he is on the speakers’ bureau of Scios Inc. • *Franklin Michota, MD*, reported that he serves as a consultant to Scios Inc.The following panelist indicated that she has no relationships that, in the context of this supplement, could be perceived as a potential conflict of interest:• *Natalie G. Correia, DO* |